Concepts (218)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Renal Insufficiency, Chronic | 12 | 2025 | 128 | 5.130 |
Why?
|
| Cardiovascular Diseases | 10 | 2025 | 832 | 3.660 |
Why?
|
| Albuminuria | 4 | 2025 | 31 | 2.770 |
Why?
|
| Diabetic Nephropathies | 6 | 2023 | 38 | 2.620 |
Why?
|
| Mortality | 3 | 2024 | 160 | 2.330 |
Why?
|
| Diabetes Mellitus, Type 2 | 6 | 2025 | 690 | 2.270 |
Why?
|
| Immunoglobulin Light-chain Amyloidosis | 3 | 2024 | 6 | 2.070 |
Why?
|
| Kidney Failure, Chronic | 4 | 2025 | 205 | 1.930 |
Why?
|
| Hyponatremia | 3 | 2022 | 13 | 1.660 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 204 | 1.630 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 218 | 1.620 |
Why?
|
| Metabolic Syndrome | 2 | 2025 | 142 | 1.620 |
Why?
|
| Kidney | 7 | 2025 | 444 | 1.570 |
Why?
|
| Nutrition Surveys | 4 | 2024 | 142 | 1.460 |
Why?
|
| Glomerular Filtration Rate | 6 | 2024 | 112 | 1.390 |
Why?
|
| Kidney Diseases | 4 | 2025 | 174 | 1.390 |
Why?
|
| Betacoronavirus | 3 | 2020 | 179 | 1.310 |
Why?
|
| Acute Kidney Injury | 4 | 2024 | 143 | 1.180 |
Why?
|
| Biomarkers | 6 | 2025 | 1388 | 1.180 |
Why?
|
| Pandemics | 4 | 2020 | 664 | 1.110 |
Why?
|
| Amyloidosis | 2 | 2024 | 63 | 1.050 |
Why?
|
| Humans | 53 | 2025 | 62868 | 1.040 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 3 | 2025 | 13 | 0.970 |
Why?
|
| Metabolic Diseases | 1 | 2025 | 57 | 0.900 |
Why?
|
| Adiposity | 1 | 2024 | 83 | 0.880 |
Why?
|
| Creatinine | 5 | 2024 | 135 | 0.830 |
Why?
|
| Water Intoxication | 1 | 2022 | 1 | 0.800 |
Why?
|
| Polydipsia, Psychogenic | 1 | 2022 | 1 | 0.800 |
Why?
|
| Neoplasms | 3 | 2023 | 1350 | 0.800 |
Why?
|
| Risk Factors | 10 | 2025 | 5309 | 0.790 |
Why?
|
| Resuscitation | 1 | 2023 | 67 | 0.790 |
Why?
|
| Social Determinants of Health | 1 | 2024 | 128 | 0.780 |
Why?
|
| Kidney Transplantation | 1 | 2024 | 314 | 0.720 |
Why?
|
| Liver Cirrhosis | 1 | 2023 | 171 | 0.720 |
Why?
|
| Naphthyridines | 1 | 2021 | 6 | 0.720 |
Why?
|
| Coronavirus | 1 | 2020 | 14 | 0.700 |
Why?
|
| ADAM17 Protein | 1 | 2020 | 8 | 0.690 |
Why?
|
| Renal Dialysis | 4 | 2019 | 198 | 0.670 |
Why?
|
| Lactic Acid | 1 | 2020 | 75 | 0.670 |
Why?
|
| Adult | 17 | 2025 | 16672 | 0.650 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2020 | 65 | 0.650 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2020 | 143 | 0.630 |
Why?
|
| Diabetes Mellitus | 3 | 2025 | 536 | 0.610 |
Why?
|
| Renal Insufficiency | 2 | 2024 | 67 | 0.610 |
Why?
|
| Antihypertensive Agents | 1 | 2020 | 171 | 0.600 |
Why?
|
| Heart Failure | 3 | 2023 | 901 | 0.600 |
Why?
|
| Incidence | 5 | 2024 | 1373 | 0.590 |
Why?
|
| Hypertension | 5 | 2025 | 590 | 0.580 |
Why?
|
| Disease Progression | 7 | 2024 | 1159 | 0.540 |
Why?
|
| Hyperoxaluria | 3 | 2024 | 10 | 0.540 |
Why?
|
| Peptidyl-Dipeptidase A | 3 | 2020 | 44 | 0.510 |
Why?
|
| Aged | 17 | 2025 | 14271 | 0.500 |
Why?
|
| Middle Aged | 15 | 2025 | 17394 | 0.480 |
Why?
|
| Female | 22 | 2025 | 32566 | 0.480 |
Why?
|
| Prospective Studies | 7 | 2024 | 3263 | 0.470 |
Why?
|
| Vascular Access Devices | 1 | 2015 | 15 | 0.470 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2015 | 44 | 0.460 |
Why?
|
| Risk Assessment | 4 | 2025 | 2051 | 0.460 |
Why?
|
| Patient Preference | 1 | 2015 | 83 | 0.450 |
Why?
|
| Male | 20 | 2025 | 29552 | 0.440 |
Why?
|
| Bleaching Agents | 1 | 2013 | 6 | 0.410 |
Why?
|
| Sodium Hypochlorite | 1 | 2013 | 12 | 0.410 |
Why?
|
| Pregnancy Complications | 1 | 2018 | 378 | 0.410 |
Why?
|
| Diuretics | 2 | 2025 | 63 | 0.400 |
Why?
|
| Hyperlipidemias | 1 | 2012 | 34 | 0.390 |
Why?
|
| Prognosis | 4 | 2024 | 1727 | 0.390 |
Why?
|
| Republic of Korea | 2 | 2024 | 164 | 0.380 |
Why?
|
| Receptors, Mineralocorticoid | 2 | 2022 | 4 | 0.380 |
Why?
|
| Patient Safety | 1 | 2015 | 242 | 0.380 |
Why?
|
| Patient-Centered Care | 1 | 2015 | 253 | 0.380 |
Why?
|
| Cause of Death | 2 | 2024 | 222 | 0.370 |
Why?
|
| Puerperal Disorders | 1 | 2011 | 15 | 0.370 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 1 | 2011 | 13 | 0.370 |
Why?
|
| Cohort Studies | 5 | 2025 | 2549 | 0.350 |
Why?
|
| Machine Learning | 2 | 2024 | 175 | 0.350 |
Why?
|
| Mother-Child Relations | 1 | 2011 | 46 | 0.340 |
Why?
|
| Signal Transduction | 1 | 2020 | 3027 | 0.330 |
Why?
|
| United States | 4 | 2024 | 7744 | 0.300 |
Why?
|
| Pneumonia | 1 | 2011 | 288 | 0.290 |
Why?
|
| Albumins | 2 | 2024 | 35 | 0.270 |
Why?
|
| Recovery of Function | 3 | 2024 | 282 | 0.260 |
Why?
|
| Communication | 1 | 2011 | 569 | 0.250 |
Why?
|
| Aldosterone | 2 | 2022 | 18 | 0.240 |
Why?
|
| Potassium | 2 | 2022 | 101 | 0.240 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2024 | 16 | 0.230 |
Why?
|
| Nephrologists | 1 | 2024 | 7 | 0.230 |
Why?
|
| Waist Circumference | 1 | 2024 | 45 | 0.230 |
Why?
|
| Osteopontin | 1 | 2024 | 21 | 0.230 |
Why?
|
| Foreign-Body Migration | 1 | 2024 | 21 | 0.220 |
Why?
|
| Stroke | 2 | 2024 | 1190 | 0.220 |
Why?
|
| Time Factors | 2 | 2024 | 3749 | 0.220 |
Why?
|
| Angiotensins | 2 | 2020 | 4 | 0.220 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2024 | 74 | 0.210 |
Why?
|
| Device Removal | 1 | 2024 | 65 | 0.210 |
Why?
|
| Kidney Glomerulus | 1 | 2023 | 22 | 0.210 |
Why?
|
| Aphasia | 1 | 2024 | 44 | 0.210 |
Why?
|
| Atrial Appendage | 1 | 2024 | 33 | 0.210 |
Why?
|
| Cystatin C | 1 | 2023 | 8 | 0.210 |
Why?
|
| Fluid Therapy | 1 | 2023 | 49 | 0.200 |
Why?
|
| Apolipoprotein L1 | 1 | 2022 | 6 | 0.200 |
Why?
|
| Neovascularization, Pathologic | 1 | 2023 | 140 | 0.200 |
Why?
|
| Proteomics | 1 | 2024 | 284 | 0.200 |
Why?
|
| Sodium-Glucose Transporter 2 | 1 | 2022 | 6 | 0.190 |
Why?
|
| Canagliflozin | 1 | 2022 | 6 | 0.190 |
Why?
|
| Body Mass Index | 2 | 2024 | 864 | 0.190 |
Why?
|
| India | 2 | 2024 | 157 | 0.190 |
Why?
|
| Models, Immunological | 1 | 2022 | 85 | 0.190 |
Why?
|
| Follow-Up Studies | 3 | 2024 | 2444 | 0.180 |
Why?
|
| Patient Selection | 1 | 2024 | 482 | 0.180 |
Why?
|
| Chronic Disease | 1 | 2024 | 749 | 0.180 |
Why?
|
| Young Adult | 2 | 2024 | 4655 | 0.180 |
Why?
|
| Renin-Angiotensin System | 1 | 2020 | 22 | 0.180 |
Why?
|
| Hypophosphatemia, Familial | 1 | 2020 | 4 | 0.170 |
Why?
|
| Sodium-Phosphate Cotransporter Proteins, Type IIa | 1 | 2020 | 4 | 0.170 |
Why?
|
| Nephrolithiasis | 1 | 2020 | 8 | 0.170 |
Why?
|
| Ascites | 1 | 2020 | 21 | 0.170 |
Why?
|
| Glucosides | 1 | 2020 | 13 | 0.170 |
Why?
|
| Ions | 1 | 2020 | 56 | 0.170 |
Why?
|
| Osmolar Concentration | 1 | 2020 | 89 | 0.170 |
Why?
|
| Practice Guidelines as Topic | 1 | 2024 | 727 | 0.170 |
Why?
|
| Catheters, Indwelling | 1 | 2020 | 69 | 0.170 |
Why?
|
| Atherosclerosis | 1 | 2022 | 152 | 0.170 |
Why?
|
| Vasodilation | 1 | 2020 | 36 | 0.170 |
Why?
|
| Lung Injury | 1 | 2020 | 33 | 0.170 |
Why?
|
| Drainage | 1 | 2020 | 154 | 0.160 |
Why?
|
| Benzhydryl Compounds | 1 | 2020 | 51 | 0.160 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2019 | 34 | 0.160 |
Why?
|
| Drug Discovery | 1 | 2020 | 95 | 0.160 |
Why?
|
| Immunity | 1 | 2020 | 107 | 0.160 |
Why?
|
| Virus Internalization | 1 | 2020 | 87 | 0.160 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 160 | 0.160 |
Why?
|
| Cross-Sectional Studies | 3 | 2025 | 2558 | 0.150 |
Why?
|
| Proportional Hazards Models | 1 | 2020 | 729 | 0.150 |
Why?
|
| Calcium | 1 | 2022 | 574 | 0.150 |
Why?
|
| Maternal Mortality | 1 | 2018 | 13 | 0.140 |
Why?
|
| Infant Mortality | 1 | 2018 | 20 | 0.140 |
Why?
|
| Pregnancy | 2 | 2018 | 2326 | 0.140 |
Why?
|
| Treatment Outcome | 3 | 2024 | 5596 | 0.140 |
Why?
|
| Oxalates | 3 | 2024 | 19 | 0.140 |
Why?
|
| Gene Expression | 1 | 2020 | 838 | 0.130 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2021 | 730 | 0.130 |
Why?
|
| Aged, 80 and over | 2 | 2020 | 5411 | 0.130 |
Why?
|
| Up-Regulation | 1 | 2018 | 375 | 0.130 |
Why?
|
| Pregnancy Outcome | 1 | 2018 | 193 | 0.130 |
Why?
|
| Myocardial Infarction | 1 | 2023 | 910 | 0.120 |
Why?
|
| Comorbidity | 2 | 2025 | 1119 | 0.120 |
Why?
|
| Atrial Fibrillation | 1 | 2024 | 836 | 0.120 |
Why?
|
| Algorithms | 1 | 2020 | 1003 | 0.120 |
Why?
|
| Vascular Grafting | 1 | 2015 | 39 | 0.110 |
Why?
|
| Coronary Disease | 2 | 2012 | 246 | 0.110 |
Why?
|
| Precision Medicine | 1 | 2015 | 119 | 0.110 |
Why?
|
| Prevalence | 1 | 2018 | 1366 | 0.110 |
Why?
|
| Infant, Newborn | 1 | 2018 | 1348 | 0.100 |
Why?
|
| Injections, Intravenous | 1 | 2013 | 156 | 0.100 |
Why?
|
| Infant | 1 | 2018 | 1623 | 0.100 |
Why?
|
| Patient Participation | 1 | 2015 | 229 | 0.100 |
Why?
|
| Severity of Illness Index | 1 | 2018 | 1541 | 0.100 |
Why?
|
| Vascular Surgical Procedures | 1 | 2015 | 257 | 0.100 |
Why?
|
| Suicide, Attempted | 1 | 2013 | 106 | 0.100 |
Why?
|
| Epilepsy, Tonic-Clonic | 1 | 2011 | 8 | 0.090 |
Why?
|
| Neurologic Examination | 1 | 2011 | 52 | 0.090 |
Why?
|
| Obesity | 1 | 2019 | 1230 | 0.090 |
Why?
|
| Child | 1 | 2020 | 4477 | 0.090 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2012 | 217 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2018 | 1589 | 0.080 |
Why?
|
| Ambulatory Care | 1 | 2012 | 311 | 0.080 |
Why?
|
| Patients | 1 | 2011 | 111 | 0.080 |
Why?
|
| Health Behavior | 1 | 2011 | 466 | 0.070 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2012 | 709 | 0.070 |
Why?
|
| Health Promotion | 1 | 2011 | 492 | 0.060 |
Why?
|
| Mice | 1 | 2020 | 10819 | 0.060 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2011 | 755 | 0.060 |
Why?
|
| Retrospective Studies | 2 | 2020 | 6548 | 0.060 |
Why?
|
| United Kingdom | 1 | 2025 | 79 | 0.060 |
Why?
|
| Biological Specimen Banks | 1 | 2025 | 23 | 0.060 |
Why?
|
| Tenascin | 1 | 2024 | 4 | 0.060 |
Why?
|
| Kidney Tubules | 1 | 2024 | 21 | 0.060 |
Why?
|
| Blood Proteins | 1 | 2024 | 76 | 0.060 |
Why?
|
| Curcuma | 1 | 2024 | 2 | 0.060 |
Why?
|
| Aortography | 1 | 2024 | 57 | 0.060 |
Why?
|
| Aorta, Abdominal | 1 | 2024 | 59 | 0.050 |
Why?
|
| Embolism | 1 | 2024 | 41 | 0.050 |
Why?
|
| Urinalysis | 1 | 2023 | 38 | 0.050 |
Why?
|
| Single-Cell Analysis | 1 | 2024 | 113 | 0.050 |
Why?
|
| Computed Tomography Angiography | 1 | 2024 | 123 | 0.050 |
Why?
|
| Prosthesis Design | 1 | 2024 | 223 | 0.050 |
Why?
|
| Proteinuria | 1 | 2023 | 41 | 0.050 |
Why?
|
| Urea | 1 | 2022 | 37 | 0.050 |
Why?
|
| Sodium | 1 | 2022 | 62 | 0.050 |
Why?
|
| Renal Elimination | 1 | 2022 | 3 | 0.050 |
Why?
|
| Adolescent | 1 | 2013 | 6195 | 0.050 |
Why?
|
| Cardiac Catheterization | 1 | 2024 | 280 | 0.050 |
Why?
|
| Animals | 1 | 2020 | 20617 | 0.050 |
Why?
|
| Biopsy | 1 | 2023 | 431 | 0.050 |
Why?
|
| Thrombosis | 1 | 2024 | 199 | 0.050 |
Why?
|
| Dietary Supplements | 1 | 2024 | 233 | 0.050 |
Why?
|
| Phosphorus | 1 | 2020 | 16 | 0.040 |
Why?
|
| Renin | 1 | 2020 | 10 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2022 | 578 | 0.040 |
Why?
|
| Genotype | 1 | 2022 | 666 | 0.040 |
Why?
|
| Plasma | 1 | 2020 | 37 | 0.040 |
Why?
|
| Boston | 1 | 2020 | 251 | 0.040 |
Why?
|
| Transcriptome | 1 | 2023 | 385 | 0.040 |
Why?
|
| Models, Theoretical | 1 | 2021 | 271 | 0.040 |
Why?
|
| Sex Factors | 1 | 2022 | 975 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2022 | 453 | 0.040 |
Why?
|
| Computer Simulation | 1 | 2021 | 477 | 0.040 |
Why?
|
| Anti-Infective Agents | 1 | 2019 | 150 | 0.040 |
Why?
|
| Phenotype | 1 | 2021 | 1197 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 964 | 0.030 |
Why?
|
| Cytokines | 1 | 2021 | 934 | 0.030 |
Why?
|
| Brain | 1 | 2024 | 1554 | 0.030 |
Why?
|
| Immunity, Innate | 1 | 2021 | 794 | 0.030 |
Why?
|
| Inflammation | 1 | 2019 | 1142 | 0.020 |
Why?
|
| Cholesterol | 1 | 2011 | 259 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2011 | 514 | 0.020 |
Why?
|
| Smoking | 1 | 2011 | 864 | 0.020 |
Why?
|
| Exercise | 1 | 2011 | 938 | 0.010 |
Why?
|